期刊文献+

联合硝普钠、多巴胺微量泵治疗肺结核肺心病心衰疗效观察 被引量:7

Curative effect observation of combination of sodium nitroprusside and dopamine with Microinfusion pump in treatment chronic heart failure of Corpulmonale in pulmonary tuberculosis
下载PDF
导出
摘要 目的联合硝普钠、多巴胺微量泵治疗肺结核肺心病患者慢性心力衰竭(CHF)疗效观察。方法 71例CHF患者随机分为36例硝普钠、多巴胺微量泵治疗组和35例常规治疗对照组。治疗组在对照组的基础上用NS50ML,硝普钠20mg,多巴胺200mg,微量泵恒速注射,平均剂量1h 5mL,每天1次。结果治疗组中有29例心衰症状改善,总有效率91.67%,心衰症状改善平均5.8d。血压无明显变化,心率减慢;对照组有25例心衰症状改善,总有效率71.43%,心衰症状改善平均10.4d,两者比较差异显著(P<0.05)。结论联合硝普钠、多巴胺微量泵治疗肺结核肺心病心力衰竭有明显疗效,且能控制输液量,使用方便,经济、安全。 OBJECTIVE To observe the effects of combination of sodium nitroprusside and dopamine with Microinfusion pump in treatment chronic heart failure of Corpulmonale in pulmonary tuberculosis.METHODS 71 patients with CHF were randomed into 36 cases sodium nitroprusside 20mg and dopamine 200mg qd with Microinfusion pump treatment group and 35 cases control treatment group.RESLUTS 33 patients had obvious improved condition of heart failure;total efficiency rate 91.67%,average improvement 5.8 days,blood pressure had no change,heart rate decreased in treatment group;25 patients had obvious improved condition of heart failure,total efficiency rate 71.43%,average improvement 10.4 days in control treatment group.compared with them showed difference(P〈0.05).CONCLUSION To observe the effects of combination of sodium nitroprusside and dopamine with Microinfusion pump in treatment chronic heart failure of Corpulmonale;in pulmonary tuberculosis and can control injection liquid.used convenience,economy ,safety.
出处 《海峡药学》 2010年第10期103-105,共3页 Strait Pharmaceutical Journal
关键词 硝普钠 多巴胺 微量泵 肺结核 肺心病 心力衰竭 疗效 Sodium nitroprusside dopamine Microinfusion pump pulmonary tuberculosis Corpulmonale Chronic heart failure Efficiency
  • 相关文献

参考文献2

二级参考文献6

共引文献27

同被引文献24

  • 1谢洪智,朱文玲.重组人脑利钠肽和硝酸甘油治疗急性失代偿性心力衰竭疗效和安全性的随机、开放、平行对照的多中心临床研究[J].中华心血管病杂志,2006,34(3):222-226. 被引量:228
  • 2Sudoh T, Kangawa K, Minamino N, et al. A new natriurctic peptide in porcine brain. Nature 1988,332(6159) :78-81.
  • 3马长生,胡大一,王显,等.心脏病学实践2010-规范化治疗.北京:人民卫生出版社,2010:375-381.
  • 4Nishikimi T, Maeda N, Matsuoka H. The role of natriuretic peptides in cardioprotection. Cardiovascular Research, 2006, 69(2):318-328.
  • 5中华医学会心血管病学分会,中华心血管病杂志编辑委员会.2007中国慢性心力衰竭诊断治疗指南.中华心血管病杂志,2007,35(12):1-29.
  • 6马长生,胡大一,王显,等.2010:心脏病学实践规范化治疗.北京:人民卫生出版社,2010:375-381.
  • 7Colucci WS, Elkayam U, Bourge RC, et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. N Engl J Med, 2000, 343(4):246-253.
  • 8Aronson D, Burger AJ. Intravenous nesiritide (human B-type natriuretic peptide) reduces plasma endothelin-1 levels in patients with decompensated congestive heart failure. Am J Cardiol, 2002, 90(4):435-438.
  • 9Cataliotti A, Boerrigter G, Costello-Boerrigter LC, et al. Brain natriuretic peptide enhances renal actions of furosemide and suppresses furosemide-induced aldosterone activation in experimental heart failure. Circulation, 2004, 109(5Suppl 1):1680- 1685.
  • 10Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol, 2013, 62(16):e147-e239.

引证文献7

二级引证文献49

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部